JP2004504347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504347A5 JP2004504347A5 JP2002513458A JP2002513458A JP2004504347A5 JP 2004504347 A5 JP2004504347 A5 JP 2004504347A5 JP 2002513458 A JP2002513458 A JP 2002513458A JP 2002513458 A JP2002513458 A JP 2002513458A JP 2004504347 A5 JP2004504347 A5 JP 2004504347A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- histone
- histone deacetylase
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 102000003964 Histone deacetylase Human genes 0.000 claims 12
- 108090000353 Histone deacetylase Proteins 0.000 claims 12
- 238000000034 method Methods 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 108010033040 Histones Proteins 0.000 claims 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 4
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 4
- 229960000604 valproic acid Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000006947 Histones Human genes 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000006197 histone deacetylation Effects 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 claims 1
- 102100038715 Histone deacetylase 8 Human genes 0.000 claims 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 claims 1
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 claims 1
- 108010044467 Isoenzymes Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 102000015694 estrogen receptors Human genes 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000037426 transcriptional repression Effects 0.000 claims 1
- 230000011199 transformed cell apoptotic process Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Claims (16)
- R1およびR2が独立して、1個の二重結合または三重結合を含んでいてもよい直鎖状または分岐状の炭素数2〜10の炭化水素鎖であることを特徴とする請求項1に記載の使用。
- 前記化合物がバルプロ酸(VPA)、S−4−yn VPA、2−EHXA(2−エチルヘキサン酸)およびそれらの医薬上許容される塩から選ばれることを特徴とする請求項1または2に記載の使用。
- ヒストン脱アセチル化活性を有する前記酵素が、哺乳類の、好ましくはヒトのヒストン脱アセチル化酵素であることを特徴とする請求項1〜3のいずれかに記載の使用。
- 前記ヒトのヒストン脱アセチル化酵素が、HDAC1〜HDAC8から選ばれることを特徴とする請求項4に記載の使用。
- 前記化合物が細胞の分化誘導に用いられることを特徴とする請求項1〜5のいずれかに記載の使用。
- 前記化合物が形質転換細胞の分化誘導に用いられることを特徴とする請求項6に記載の使用。
- 前記化合物が形質転換細胞のアポトーシス誘導に用いられることを特徴とする請求項1〜5のいずれかに記載の使用。
- ヒストンの高アセチル化誘導が有効である疾病の治療剤を製造するための請求項1〜3のいずれかに記載の化合物の使用。
- 患者の体内で請求項1〜3のいずれかに記載の化合物へと代謝される物質の、ヒストンの高アセチル化誘導が有効である疾病の治療剤を製造するための使用。
- 前記疾病が皮膚癌、エストロゲン受容体依存型および非依存型乳癌、卵巣癌、前立腺癌、腎臓癌、結腸直腸癌、膵臓癌、頭頸部癌、小細胞肺癌および非小細胞肺癌、および甲状腺抵抗性症候群等のヒストン脱アセチル化酵素の異常増に起因する内分泌性疾患であることを特徴とする請求項9または10に記載の使用。
- 請求項1〜3のいずれかに記載の化合物を提供し、該化合物の誘導体のヒストン脱アセチル化酵素阻害活性を測定し、ヒストン脱アセチル化酵素阻害活性を有する物質を選別することを特徴とするヒストン脱アセチル化酵素阻害活性を有する物質の同定方法。
- 前記方法が、化合物の鎮静効果を評価する段階、およびヒストン脱アセチル化酵素阻害活性およびバルプロ酸より低い鎮静効果を有する化合物を選別する段階を含むことを特徴とする請求項12に記載の方法。
- 前記ヒストン脱アセチル化酵素阻害活性が、転写抑制検定法、ヒストンH3またはH4のアセチル化検出のためのウェスタンブロット法、または脱アセチル化酵素検定法によって測定されることを特徴とする請求項12または13に記載の方法。
- 化合物のHDACへの結合及び/またはHDACへの結合の競合を測定することを特徴とする請求項1〜3のいずれかに記載の化合物のHDACイソ酵素特異性を識別する方法。
- HDACのサブセットのみを特異的に阻害する化合物を選別することを特徴とする請求項15に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00114088A EP1170008A1 (en) | 2000-07-07 | 2000-07-07 | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
PCT/EP2001/007704 WO2002007722A2 (en) | 2000-07-07 | 2001-07-05 | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004504347A JP2004504347A (ja) | 2004-02-12 |
JP2004504347A5 true JP2004504347A5 (ja) | 2005-02-03 |
Family
ID=8169134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002513458A Ceased JP2004504347A (ja) | 2000-07-07 | 2001-07-05 | ヒストン脱アセチル化酵素阻害剤としてのバルプロ酸およびその誘導体 |
Country Status (10)
Country | Link |
---|---|
US (2) | US7265154B2 (ja) |
EP (2) | EP1170008A1 (ja) |
JP (1) | JP2004504347A (ja) |
AT (1) | ATE295725T1 (ja) |
AU (2) | AU2001283925B2 (ja) |
CA (1) | CA2414967C (ja) |
DE (1) | DE60110912T2 (ja) |
ES (1) | ES2239677T3 (ja) |
PT (1) | PT1301184E (ja) |
WO (1) | WO2002007722A2 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1170008A1 (en) | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
GB0024362D0 (en) * | 2000-10-05 | 2000-11-22 | Glaxo Group Ltd | Medicaments |
WO2003018767A2 (en) * | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
US20040087657A1 (en) | 2001-10-16 | 2004-05-06 | Richon Victoria M. | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
DE60331297D1 (de) | 2002-03-07 | 2010-04-01 | Univ Delaware | Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff |
IL149404A0 (en) * | 2002-04-29 | 2002-11-10 | Yissum Res Dev Co | METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION |
GB0226855D0 (en) | 2002-11-18 | 2002-12-24 | Queen Mary & Westfield College | Histone deacetylase inhibitors |
AU2003288433B2 (en) * | 2002-12-05 | 2009-06-25 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
US7375228B2 (en) * | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
EP1491188A1 (en) * | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
ES2308065T3 (es) * | 2004-04-30 | 2008-12-01 | Topotarget Germany Ag | Formulacion que comprende un inhibidor de histona desacetilasa, que exhibe una liberacion bifasica. |
KR100659779B1 (ko) | 2004-09-04 | 2006-12-19 | 주식회사 바이넥스 | 히스톤 디아세틸라제 억제제를 함유하는 중간엽줄기세포의 골분화유도용 조성물 및 이를 이용한 골분화증가방법 |
JP2008524246A (ja) * | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
JP2008540574A (ja) * | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
WO2007084390A2 (en) * | 2006-01-13 | 2007-07-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US8338482B2 (en) * | 2006-07-20 | 2012-12-25 | Wisconsin Alumni Research Foundation | Modulating notch1 signaling pathway for treating neuroendocrine tumors |
US20080085874A1 (en) * | 2006-08-28 | 2008-04-10 | The Regents Of The University Of California | Small molecule potentiator of hormonal therapy for breast cancer |
GB0620823D0 (en) | 2006-10-19 | 2006-11-29 | Univ London | Histone deacetylase inhibitors |
CN101626763A (zh) * | 2006-12-06 | 2010-01-13 | 北海道公立大学法人札幌医科大学 | 使用组蛋白脱乙酰酶(hdac)抑制物的细胞免疫增强 |
US20090023186A1 (en) * | 2007-07-22 | 2009-01-22 | Excellgene Sa | Use of valproic acid for enhancing production of recombinant proteins in mammalian cells |
BRPI0821247A2 (pt) * | 2007-12-14 | 2015-06-16 | Univ Georgetown | Inibidores de histona deacetilase |
US8623853B2 (en) | 2008-07-23 | 2014-01-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancers characterized by chromosomal rearrangement of the NUT gene |
ES2473792T3 (es) | 2009-04-03 | 2014-07-07 | Naturewise Biotech & Medicals Corporation | Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa |
US7994357B2 (en) | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
EP2277387B1 (en) | 2009-07-22 | 2016-10-19 | NatureWise Biotech & Medicals Corporation | New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly |
EP2475769B1 (en) * | 2009-09-07 | 2016-11-09 | Jawaharlal Nehru Centre for Advanced Scientific Research | Inhibition of histone acetyltransferases by ctk7a and methods thereof |
US8921533B2 (en) | 2011-07-25 | 2014-12-30 | Chromatin Technologies | Glycosylated valproic acid analogs and uses thereof |
EP3052662B1 (en) | 2013-10-01 | 2019-05-15 | The J. David Gladstone Institutes | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
EP3137085A4 (en) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
CN105622712B (zh) * | 2014-10-27 | 2019-08-27 | 天津金耀集团有限公司 | 一种甾体3-酮-4-烯物合成工艺 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
US20210386787A1 (en) * | 2018-10-12 | 2021-12-16 | Life Technologies Corporation | Hematopoietic Stem and Progenitor Cell Expansion System |
CN111358777A (zh) * | 2020-02-24 | 2020-07-03 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种提高外周血单个核细胞线粒体功能的方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672746A (en) * | 1994-08-30 | 1997-09-30 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
US6300373B1 (en) * | 1993-09-10 | 2001-10-09 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
WO1995011699A1 (en) * | 1993-10-29 | 1995-05-04 | The Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
JPH11514857A (ja) * | 1995-09-20 | 1999-12-21 | メルク エンド カンパニー インコーポレーテッド | 抗原虫剤の標的としてのヒストンデアセチラーゼ |
US6777217B1 (en) * | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
WO1997047307A1 (en) * | 1996-06-14 | 1997-12-18 | The Uab Research Foundation | Use of histone deacetylase inhibitors to activate transgene expression |
EP0961614A4 (en) * | 1996-12-30 | 2002-07-24 | Univ Bar Ilan | OXYALKYLESTERS CONTAINING TRICARBOXYLIC ACID AND USES THEREOF |
US6387673B1 (en) * | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
AU1395999A (en) * | 1997-11-10 | 1999-05-31 | Salk Institute For Biological Studies, The | Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases |
US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
EP1170008A1 (en) | 2000-07-07 | 2002-01-09 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
-
2000
- 2000-07-07 EP EP00114088A patent/EP1170008A1/en not_active Withdrawn
-
2001
- 2001-07-05 DE DE60110912T patent/DE60110912T2/de not_active Expired - Lifetime
- 2001-07-05 AU AU2001283925A patent/AU2001283925B2/en not_active Ceased
- 2001-07-05 AU AU8392501A patent/AU8392501A/xx active Pending
- 2001-07-05 EP EP01962831A patent/EP1301184B1/en not_active Expired - Lifetime
- 2001-07-05 PT PT01962831T patent/PT1301184E/pt unknown
- 2001-07-05 WO PCT/EP2001/007704 patent/WO2002007722A2/en active IP Right Grant
- 2001-07-05 ES ES01962831T patent/ES2239677T3/es not_active Expired - Lifetime
- 2001-07-05 CA CA002414967A patent/CA2414967C/en not_active Expired - Fee Related
- 2001-07-05 JP JP2002513458A patent/JP2004504347A/ja not_active Ceased
- 2001-07-05 US US10/332,353 patent/US7265154B2/en not_active Expired - Fee Related
- 2001-07-05 AT AT01962831T patent/ATE295725T1/de active
-
2007
- 2007-01-17 US US11/653,855 patent/US20070232696A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004504347A5 (ja) | ||
D'Oto et al. | Histone demethylases and their roles in cancer epigenetics | |
US11034666B2 (en) | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | |
Dalvai et al. | The role of histone modifications and variants in regulating gene expression in breast cancer | |
Yuan et al. | Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors | |
JP2010502731A5 (ja) | ||
JP2005512961A5 (ja) | ||
ATE295725T1 (de) | Valproinsäure und deren derivate als histondeacetylaseinhibitoren | |
KR20210049117A (ko) | 기관지 전암성 병변 중증도 및 진행과 관련된 방법 | |
JP2017538104A5 (ja) | ||
JP2016501838A (ja) | 併用療法 | |
Niu et al. | Epigenetic modifications in tumor-associated macrophages: A new perspective for an old foe | |
JP2010538654A (ja) | Per3vntr遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測 | |
KR20190123270A (ko) | 암, 당뇨병 및 신경 장애의 치료를 위한 신규한 스피로 및 사이클릭 비스-벤질리딘 프로테아좀 억제제 | |
Mahmutovic-Persson et al. | Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFNβ production in diseased bronchial epithelial cells | |
CN111094262B (zh) | 1,3-二氧六环-4,6-二酮类化合物、其制备方法、药物组合物及其应用 | |
CN1337851A (zh) | 将非cox-2选择性抑制剂的cox抑制化合物转化成为cox-2选择性抑制剂的衍生物的方法 | |
US11266617B2 (en) | Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions | |
JP2024518712A (ja) | Kdm4阻害剤による癌の処置 | |
JP2024508754A (ja) | 癌および前癌性パピローマウイルス病変を処置するための2-sリマンタジンおよび2-rリマンタジン | |
US9457016B2 (en) | Methods for treating polycystic kidney disease | |
Liu et al. | The Impact of Post-Translational Regulation of Histone on Cancer Metastasis and Cancer Chemoresistance | |
US10005727B2 (en) | Compound and analogues for tracing histone acetylation inhibitors PET imaging for diagnosis and treatment of tumors | |
Maraldi et al. | Prelamin A processing and heterochromatin dynamics in laminopathies | |
JPH02243625A (ja) | 腫瘍転移抑制剤 |